Abstract
Heated intraperitoneal chemotherapy (HIPC) is a novel treatment designed to bring high concentrations of active cytotoxic agents in direct contact with tumor cells that are disseminated within peritoneal fluid or attached to the lining surfaces of the peritoneal cavity. This treatment is often combined with radical cytoreductive surgery (tumor debulking) and is therefore performed at the time of and in association with surgery. Heating is believed to have synergistic effects with chemotherapy, although to our knowledge this has not been extensively or systematically examined in human clinical studies. The potential ability of intraperitoneal administration of cytotoxic agents to increase peritoneal-to-plasma drug ratios, or the area under the curve (AUC), and thus to enhance the effectiveness of local therapy and to diminish systemic toxicity, is an attractive approach [1]. Hyperthermia can potentiate the cytotoxicity of a variety of anticancer agents, including mitomycin C (MMC), doxorubicin, lonidamine, and cisplatin [2–4]. For MMC, this synergism is enhanced under hypoxic conditions [5].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sugarbaker PH, Landy D, Jaffe G, Pascal R. Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. Cancer 1980;65:1495–1501.
Watanabe M, Tanaka R, Hondo H, Kuroki M. Effects of antineoplastic agents and hyperthermia on cytotoxicity toward chronically hypoxic glioma cells. Int J Hyperthermia 1992;8:131–138.
Ning S, Hahn GM. Combination therapy: Lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo. Cancer Res 1991;51:5910–5914.
Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980;40: 1165–1168.
Teicher BA, Kowal CD, Kennedy KA, Sartorelli AC. Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res 1981;41: 1096–1099.
Gilley FN, Carry PY, Sayag AC. Tolerance of intraperitoneal chemohyperthermia with MMC: In vivo study in dogs. Int J Hyperthermia 1992;8:659–666.
Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Takahashi M, Konno C, Ohta M, Koike S, Kitsukawa Y, Mizutani M, Katsuji O. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer 1989;64:154–160.
Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Aramizu N, Takamizawa H. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:35–41.
Fujimara T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, Miyazaki I. Continous hyperthermic peritoneal perfusion for the treatment of peritoneal disseminiation in gastric cancers and subsequent second-look operation. Cancer 1990;65:65–71.
Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232–237.
Sudarshan G, Crawford D. Anaesthesia for intraperitoneal hyperthermic perfusion. Anaesthesia 1992;47:483–485.
Panteix G, Guillaumont M, Cherpin L, Cuichard J, Gilly FN, Carry PY, Sayag A, Salle B, Brachet A, Bienvenu J, et al. Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 1994;50:366–370 1993.
Schneebaum S, Staubus AE, Asif M, Arnold M, Martin EW. Pharmacokinetics of mitomycic C (MMC) during intraperitoneal hyperthermic perfusion (IPHP) (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1992;33:A3168.
Robert J, Barbier P, Manaster J, Jacobs E. Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice. Digestion 1968;1:229–232.
Berny C, Mialon A, Manchon M, Le KE, Panteix G, Baltassat P, Gilly FN, Carry PY, Sayag A, Braillon G. Biochemical modifications in the blood and the heated fluids during intraperitoneal chemohyperthermia. Oncology 1994;50:362–364, 1993.
Kokubun M, Fujimoto S, Shrestha RD, Kobayashi K, Okui K. Intraperitoneal hyperthermic perfusion for gastric cancer patients with peritoneal implantation (meeting abstract). Fourth International Conference on Advances in Regional Cancer Therapy June 5–7, 1989, Berchtesgaden, FRG 1989, pp ●●-●●.
Thompson CT, Bailey MK, Conroy JM, Bromley HR. Postoperative pulmonary toxicity associated with mitomycin-C therapy. South Med J 1992;85:1257–1259.
Linette DC, McGee KH, McFarland JA. Mitomycin-induced pulmonary toxicity: Case report and review of the literature. Ann Pharmacother 1992;26:481–484.
Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer 1985;55:47–50.
Regelson W, Parker G. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest 1994;4:29–42, 1986.
Pfeiffer N, FDA approves the use of Ondasetron HCl to prevent post-op nausea and vomiting. Gen Surg Laparosc News 1993;●●:14–15.
Scuderi P, Wetchler B, Sung Y-F, Mingus M, DuPen S, Claybon L, Leslie J, Talke P, Apfelbaum J, Sharifi-Azad S, Williams MF. Treatment of postoperative nausea and vomiting after outpatient surgery with the 5-HT3 antagonist ondansetron. Anesthesiology 1993;78:15–20.
White PF, Watcha MF. Are new drugs cost-effective for patients undergoing ambulatory surgery? Anesthesiology 1993;78:2–5.
Fumagelli U, Trabucchi E, Soligo M. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Surg Res 1991;50:82–87.
Fujimoto S, Shrestha RD, Kokubun M, Kobayashi K, Kiuchi S, Konno C, Ohta M, Takahashi M, Kitsukawa Y, Mizutani M, Chikenji T, Okui K. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212:592–596.
Fujimoto S, Kokubun M, Shrestha RD, Kobayashi K, Kiuchi S, Konno C, Takahashi M, Okui K. Prevention of scald injury on the peritoneo-serosal surface in advanced gastric cancer patients treated with intraperitoneal hyperthermic perfusion. Int J Hyperthermia 1991;7:543–550.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Loggie, B.W., Fleming, R.A. (1996). Complications of heated intraperitioneal chemotherapy and strategies for prevention. In: Sugarbaker, P.H. (eds) Peritoneal Carcinomatosis: Principles of Management. Cancer Treatment and Research, vol 82. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1247-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1247-5_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8531-1
Online ISBN: 978-1-4613-1247-5
eBook Packages: Springer Book Archive